Quadria Capital, a healthcare-focused private equity firm, has announced an investment of $102 million (Rs 850 crore) in NephroPlus, Asia’s largest dialysis network.
Quadria will acquire a minority stake through a combination of primary investment and the purchase of shares from existing shareholders.
The funding will bolster NephroPlus' mission to meet the growing demand for high-quality, affordable dialysis services across India and other Asian markets.
Focused on expansion
Founded in 2010, NephroPlus operates approximately 450 dialysis centers across India, the Philippines, and Uzbekistan.
With the demand for dialysis services expected to grow at a rate of over 11% annually over the next five years, Quadria Capital's backing will help the company expand further and bring its quality care to more patients.
"Our business has evolved tremendously over the past few years and today we are proud to be one of the fastest-growing and most trusted providers of high-quality dialysis to around 30,000 patients," said Vikram Vuppala, founder and CEO of NephroPlus.
"We look forward to expanding in India, our core market, while exploring further opportunities to bring our expertise and clinical excellence to more patients in other global markets," Vuppala added.
Fostering growth
Quadria Capital believes NephroPlus has the potential to significantly improve patient health outcomes while maintaining robust growth and profitability.
The investment will reinforce NephroPlus’ capacity to innovate, scale, and deliver affordable dialysis care.
"Quadria’s investment in NephroPlus underscores our ambition to invest in regional champions of Asian healthcare, who are providing high-quality, affordable healthcare to large, under-served populations," said Sunil Thakur, Partner and Head of South Asia at Quadria Capital.
"NephroPlus has demonstrated its ability to significantly improve health outcomes for its patients whilst maintaining industry-leading growth and profitability," Thakur said.
Quadria's investment portfolio
This investment marks another significant addition to Quadria Capital’s portfolio of single-specialty healthcare companies in India.
Other notable investments include eyecare chain Maxivision, global gastroenterology referral center AIG, and oncology network HCG. Quadria Capital manages assets totaling over $3.4 billion.